Skye Bioscience (FRA:09R) Moat Score: 2/10 (As of Jul. 04, 2026)


FRA:09R Skye Bioscience Inc FRA:09R
12 GF Score
Price €0.56
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Moat Score?

Skye Bioscience FRA:09R 12 Moat Score is 2 as of Jul. 04, 2026. GuruFocus rates FRA:09R with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,399 Biotechnology companies, Skye Bioscience ranks better than 58.11% on this metric.

Skye Bioscience has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Skye Bioscience has No Moat: Skye Bioscience Inc lacks significant market leadership, network effects, or strong intellectual property. The company operates in a highly competitive biotech sector with minimal customer switching costs and no evident durable cost advantages or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Skye Bioscience might have No Moat - Very weak/transient advantages.

Skye Bioscience  (FRA:09R) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Skye Bioscience Moat Score Related Terms

FRA:09R vs PLRZ, NEUP, LGVN: Moat Score Comparison

For the Biotechnology subindustry, Skye Bioscience's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skye Bioscience Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Moat Score distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Moat Score falls into.


FRA:09R
12GF Score
Skye Bioscience Inc FRA:09R
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Skye Bioscience (FRA:09R) has a Moat Score of 2 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Skye Bioscience ranks #586 out of 1399 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Skye Bioscience's Moat Score too high?
Skye Bioscience's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Skye Bioscience's value of 2 is 0% at this industry median. Based on the distribution chart, Skye Bioscience ranks #586 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Skye Bioscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Moat Score compare to PLRZ and NEUP?
According to the Biotechnology industry distribution chart, Skye Bioscience ranks #586 out of 1399 companies for Moat Score. This puts Skye Bioscience in the upper half of its industry. The industry median Moat Score is 2.00. Skye Bioscience's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Skye Bioscience's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skye Bioscience's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Skye Bioscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Moat Score is 2 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
12GF Score

Get the complete analysis for FRA:09R

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price